Inactive Instrument

Company Regenicin, Inc. Other OTC

Equities

RGIN

US75887Q1022

Biotechnology & Medical Research

Business Summary

Regenicin, Inc. is a biotechnology company that is focused on the development of regenerative cell therapies to restore the health of damaged tissues and organs. The Company is focused on developing and commercializing a lifesaving technology through the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a range of plastic surgery procedures. Its product, NovaDerm, is a multi-layered tissue-engineered skin prepared by utilizing autologous skin cells. NovaDerm is a graftable cultured epithelium skin substitute containing both epidermal and dermal components. It is focused on developing its product, TempaDerm. TempaDerm cells develop banks of cryo-preserved (frozen) cells and cultured skin substitutes to provide a continuous supply of non-allogenic skin substitutes to treat smaller wound areas in patients, such as ulcers. Its application is used for the treatment of chronic skin wounds.

Managers

Managers TitleAgeSince
Chief Executive Officer 74 10-07-14
Director of Finance/CFO 74 10-09-12
Chief Tech/Sci/R&D Officer 75 10-07-14

Members of the board

Members of the board TitleAgeSince
Director of Finance/CFO 74 10-09-12
Chief Executive Officer 74 10-07-14

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 157,911,410 125,611,409 ( 79.55 %) 4,428,360 ( 2.804 %) 79.10 %
Stock B 0 885,000 0 0

Shareholders

NameEquities%Valuation
Bartlett & Co. Wealth Management LLC
0.000000 %
0 0.000000 % - $

Company contact information

Regenicin, Inc.

10 High Court

07424, Little Falls

+

http://www.regenicin.com
address Regenicin, Inc.(RGIN)
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW